Similar articles for PMID: 32227579

Year	Number of Results
2012	1
2016	6
2017	10
2018	8
2019	12
2020	11
2021	10
2022	8
2023	2
2024	0

1

A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.

Feng X, Tang R, Zhang R, Wang H, Ji Z, Shao Y, Wang S, Zhong T, Gu Y, Meng J. Feng X, et al. J Cell Mol Med. 2020 May;24(9):5238-5248. doi: 10.1111/jcmm.15176. Epub 2020 Mar 30. J Cell Mol Med. 2020. PMID: 32227579 Free PMC article.

2

Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.

Noonepalle SK, Gu F, Lee EJ, Choi JH, Han Q, Kim J, Ouzounova M, Shull AY, Pei L, Hsu PY, Kolhe R, Shi F, Choi J, Chiou K, Huang TH, Korkaya H, Deng L, Xin HB, Huang S, Thangaraju M, Sreekumar A, Ambs S, Tang SC, Munn DH, Shi H. Noonepalle SK, et al. Cancer Immunol Res. 2017 Apr;5(4):330-344. doi: 10.1158/2326-6066.CIR-16-0182. Epub 2017 Mar 6. Cancer Immunol Res. 2017. PMID: 28264810 Free PMC article.

3

Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.

Zhou S, Yang H, Zhang J, Wang J, Liang Z, Liu S, Li Y, Pan Y, Zhao L, Xi M. Zhou S, et al. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):286-294. doi: 10.1016/j.ijrobp.2020.01.020. Epub 2020 Jan 28. Int J Radiat Oncol Biol Phys. 2020. PMID: 32004580 Free article.

4

Clinical Significance of TET2 in Female Cancers.

Wan F, Chen F, Fan Y, Chen D. Wan F, et al. Front Bioeng Biotechnol. 2022 Feb 11;10:790605. doi: 10.3389/fbioe.2022.790605. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35223782 Free PMC article.

5

ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.

Wang J, Zhang X, Li J, Ma X, Feng F, Liu L, Wu J, Sun C. Wang J, et al. Aging (Albany NY). 2020 Nov 21;13(1):351-363. doi: 10.18632/aging.104204. Epub 2020 Nov 21. Aging (Albany NY). 2020. PMID: 33234738 Free PMC article.

6

Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.

Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y. Kozuma Y, et al. Eur J Cancer. 2018 Sep;101:20-29. doi: 10.1016/j.ejca.2018.06.020. Epub 2018 Jul 13. Eur J Cancer. 2018. PMID: 30014971 Free article.

7

Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).

Anurag M, Zhu M, Huang C, Vasaikar S, Wang J, Hoog J, Burugu S, Gao D, Suman V, Zhang XH, Zhang B, Nielsen T, Ellis MJ. Anurag M, et al. J Natl Cancer Inst. 2020 Jul 1;112(7):737-746. doi: 10.1093/jnci/djz213. J Natl Cancer Inst. 2020. PMID: 31665365 Free PMC article.

8

Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.

Ebokaiwe AP, Njoya EM, Sheng Y, Zhang Z, Li S, Zhou Z, Qiang Z, Peng T, Hussein AA, Zhang G, Lu X, Li L, Wang F. Ebokaiwe AP, et al. Toxicol Appl Pharmacol. 2020 Oct 1;404:115203. doi: 10.1016/j.taap.2020.115203. Epub 2020 Aug 19. Toxicol Appl Pharmacol. 2020. PMID: 32822738

9

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.

Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, Guo J, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Pirson R, Rabolli V, Ray C, Streiner N, Torti VR, Tsaparikos K, Van den Eynde BJ, Wythes M, Yao LC, Zheng X, Tumang J, Kraus M. Gomes B, et al. Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19. Mol Cancer Ther. 2018. PMID: 30232146

10

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Carvajal-Hausdorf DE, et al. J Immunother Cancer. 2017 Oct 17;5(1):81. doi: 10.1186/s40425-017-0285-7. J Immunother Cancer. 2017. PMID: 29037255 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

61 results

Results by year